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Predicting nasal stinging, itching and burning sensations 
Joke Lenoir a, Els Adriaens a, Jean-Paul Remon a 
a Lab of Pharmaceutical Technology, Ghent University, Harelbekestraat 72,  
B – 9000 Gent, Belgium 
Short Abstract 
The objective of this study was to evaluate the mucosal tolerance of several 
marketed nasal formulations using the slug Arion lusitanicus. None of the tested 
formulations resulted in tissue damage, however a clear effect on the mucus 
production of the slugs was observed, either due to the active ingredient, presence of 
benzalkonium chloride as a preservative or hyperosmolality of the formulation. The 
new 1-day protocol of the Slug Mucosal Irritation assay is a good tool to predict nasal 
clinical discomfort.  
Abstract 
Today, stinging, itching and/or burning (SIB) sensations cannot be detected by 
animal tests or in vitro models. In the past, the Slug Mucosal Irritation (SMI) assay 
demonstrated a relation between an increased mucus production in slugs and an 
elevated incidence of SIB sensations in humans. A new 1-day SMI-test procedure 
was developed focusing on the prediction of these short term sensations. 
The objective of this study was to verify whether this new procedure is capable 
predicting mucosal tolerance of several marketed nasal formulations using the slug 
Arion lusitanicus. Irritation and tissue damage were quantified with a 5-day repeated 
exposure study by means of the mucus produced and proteins and enzymes 
released. On the other hand, the new protocol predicted SIB sensations by means of 
the mucus production. The effects of 6 liquid nasal formulations were tested with both 
protocols, while 5 physiologic saline solutions were only tested with the new protocol 
to optimize it. None of the tested liquid nasal formulations resulted in tissue damage, 
however the exposure to the different formulations had a clear effect on the mucus 
production of the slugs and moderate discomfort was observed in some cases. 
These effects were due to the active ingredient, the presence of benzalkonium 
chloride as a preservative or the hyperosmolality of the formulation. For the most part 
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results agreed with clinical data found in literature. It was concluded that the SMI 
assay and the new 1-day protocol in particular is a good tool to predict nasal clinical 
discomfort. 
Key words: nasal formulations, discomfort, mucosal tolerance, Slug Mucosal 
Irritation assay, alternative testing method 
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Introduction 
The nose serves as an efficient humidifier, heater and filter for inhaled air, thereby 
protecting the lower airways (Bousquet et al., 2001). Consequently, the nasal 
mucosa is constantly exposed to unconditioned and occasionally polluted inhaled air 
causing irritation, sneezing, reflex-mediated hyper-secretion and nasal blockage 
(Bousquet et al., 2001). The protection against invading microorganisms by the nasal 
mucosa includes an intact mucosal barrier, mucociliary transport and mucosal 
immunity (Mygind et al., 1990). Defects in any of these defense mechanisms may 
increase the susceptibility to infection (Bjerknes & Steinsvåg, 1993). 
The nasal mucosa is also a potential site for drug absorption, as the surface of the 
mucosa is large and well provided with blood vessels (Hermens & Merkus, 1987). As 
a consequence, nasal drug formulations for local use are widely used as they are 
mostly ‘over the counter’ (OTC) drugs (Romeijn et al., 1996). A number of these OTC 
nasal formulations are used to relieve congestion in patients with allergic rhinitis 
(AR), non-allergic rhinitis, acute or chronic sinusitis, nasal polyposis, and rhinitis due 
to nasal septal deviation or obstruction (Graf, 2005; Åkerlund & Bende, 1991), even 
though some decongestive nose sprays contain components with potentially 
deleterious effects on the nasal mucosa (Talaat et al., 1981; van de Donk et al., 
1981, 1982). Some of these formulations are even associated with the occurrence of 
rhinitis medicamentosa (RM), a condition first described by Kully (1945) as a therapy-
resistant nasal blockage due to overmedication with nasal decongestants.  
Suffering from RM, several histological changes may occur in the nose. Rhinitis 
medicamentosa may be induced either by the active ingredient of the formulation 
(e.g. oxymetazoline (Graf & Hallén, 1996; Min et al., 1996)) or preservatives (e.g. 
benzalkonium chloride (Graf, 1999; Graf et al., 1995; Graf & Hallén, 1996)). From 
most OTC-formulations only minimal effects are observed in vivo, but long term use 
may result in RM. This is the case, for example, when formulations with 
oxymetazoline are used longer than 10 days (Graf & Juto, 1994a, 1994b, 1995). 
In general, the development of some pharmaceutical formulations and cosmetics can 
be ceased in a later phase in the development when they cause stinging, itching 
and/or burning sensations during clinical studies. These discomforts are only seen in 
this stage since neither animal tests nor in vitro models were able to detect these 
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effects. This was the case for the Nasalide® nasal spray, containing the topical 
intranasal corticosteroid flunisolide. Trangsrud et al. (2002) noted that Nasalide® was 
associated with more reports of nasal stinging and burning. According to early reports 
of tolerability, up to 45% of patients noted nasal burning with Nasalide® nasal spray 
(Dura Pharmaceuticals Inc., 2000; Mabry, 1995). Some of these problems were due 
to the formulation. In the 1980s the drug was reformulated to contain less propylene 
glycol (Nasarel®) which resulted in a significantly lower frequency of nasal burning 
and stinging as well as throat irritation (Greenbaum et al., 1988; Meltzer et al., 1990). 
Hence, a screening method for clinical discomfort would be very helpful in the 
development and refinement process of formulations which are usually tolerated well. 
In the past, the Slug Mucosal Irritation (SMI) test, which is an alternative mucosal 
irritation method, demonstrated a relation between an increase in mucus production 
in slugs and an elevated incidence of stinging, itching and burning (SIB) in humans 
(Adriaens & Remon, 2008). The principle of the SMI-test is the fact that a higher 
mucus production is observed when slugs are exposed to more irritant substances, 
and that when tissue damage occurs, there will be protein and enzyme release. By 
means of the SMI-test we are able to predict the stinging, itching and burning (SIB) 
sensations since slugs react on these stimuli by an increase in mucus production.  
In this present study, the mucosal tolerance of several nasal formulations was 
evaluated with a 5-day repeated exposure study. Additionally, the effect of tonicity 
and the concentration of benzalkonium chloride (BAC) were investigated into detail. 
In the second part of this study, a newly developed 1-day protocol of the SMI assay is 
suggested as a new method to predict short term sensations (stinging, itching and 
burning) in man. To optimize this new protocol, several marketed physiological saline 
solutions with different tonicity were tested in addition to the nasal formulations tested 
with the 5-day protocol.  
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Materials and methods 
Materials 
Nasal formulations and controls 
Four nasal solutions were selected: Nesivine® and Nesivine® Baby (oxymetazoline 
HCl - Merck, Overijse, Belgium), Allergodil® (azelastine HCl - Meda Pharma, 
Brussels, Belgium) and Syntaris® (flunisolide - Norton Healthcare Ltd., London, 
United Kingdom). Additionally, effects of 2 nasal suspensions Flixonase Aqua™ 
(fluticasone propionate - GlaxoSmithKline, Genval, Belgium) and Nasonex® 
(mometasone furoate - Schering-Plough NV/SA, Brussels, Belgium) were also 
investigated. All nasal formulations were studied in undiluted form. The details of the 
tested formulations are listed in Table 1. 
Additionally, isotonic nasal physiological salt solutions Naaprep® (GlaxoSmithKline, 
Mary-le-Roi, France), Rhina-Care (Sanofi-Aventis, Diegem, Belgium) and 
Physiomer® Normal Jet (Goëmar, Saint-Malo, France) were also tested with the 
newly developed protocol. Moreover, possible effects of the hypertonic solutions 
Sinomarin® (Belobal, Paris, France – 2.3% NaCl) and Physiomer® Sinus (Goëmar, 
Saint-Malo, France – 2.2% NaCl) were investigated as well. 
In the experiments phosphate buffered saline (PBS, pH 7.4) was used as a negative 
control, whereas a 1% (w/v) dilution of benzalkonium chloride (BAC) (both delivered 
by Sigma, St Louis, MO, USA) was used as a positive control. 
 
Methods 
Local tolerance test procedure of the SMI-test  
The slugs (Arion lusitanicus) were born in the lab in October-December 2008 and 
bred in an acclimatized room (18-20°C). Slugs weighing between 3 g and 6 g were 
isolated two days before the start of an experiment and placed in a plastic box lined 
with a paper towel (moistened with PBS) at 18-20°C. During the isolation period, the 
body wall of the slugs was daily wetted with 1 ml PBS using a micropipette. 
The effect of the 6 selected nasal formulations, negative and positive controls on the 
mucosal tissue of the slugs was investigated. All nasal formulations were tested pure. 
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The slugs and Petri dishes, where they were put on during the contact period (CP), 
were weighed at the beginning of the experiment. Subsequently, the slugs were 
placed individually during 30 minutes in a Petri dish on 100 µl of test medium. For 
each series, five slugs were used. Each experimental run also contained a negative 
(PBS) and a positive control (BAC, 1% w/v). After the CP, the amount of mucus 
produced was measured by reweighing the Petri dishes containing the test medium 
(without the slugs). The mucus production (MP) is expressed as a percentage (w/w) 
of the initial body weight. Next, the slugs were transferred to a fresh Petri dish and 1 
ml PBS was added. One hour later, the PBS samples were collected with a 
micropipette and were analyzed immediately for the presence of proteins, lactate 
dehydrogenase (LDH), and alkaline phosphatase (ALP) released from the slug body 
wall. Finally, the slugs were transferred to a fresh Petri dish and again 1 ml PBS was 
added. The second PBS samples were collected after 60 minutes. Again, the 
samples were analyzed immediately for the presence of proteins, LDH, and ALP. 
This procedure was repeated for 5 successive days. 
Additionally, the influence of osmolality and BAC-concentration was investigated to 
deduce the possible effect of these factors. A concentration-response experiment 
was conducted testing the irritation potency of BAC in a concentration of (w/v) 0.02%, 
0.1%, 0.5% and 1%, while the effect of tonicity was investigated testing 6 different 
concentrations (w/v) of NaCl (0.05%, 0.5%, 0.9%, 2.5%, 5% and 10%). These 
experiments followed the procedure described above. 
 
Analytical procedures 
 Protein determination  
The total protein concentration present in the PBS-samples was determined with a 
NanoOrange® protein quantification kit (Invitrogen™, Merelbeke, Belgium) and 
expressed as µg/ml per gram body weight. The NanoOrange® reagent allows 
accurate detection of proteins in solution at concentrations between 10 ng/ml and 10 
μg/ml (Harvey et al., 2001). The fluorescence measurements were carried out on a 
fluorometer (Wallac 1420 multilabel counter Victor 2, PerkinElmer, Turku, Finland) 
using excitation/emission wavelengths of 485/590 nm. Bovine serum albumin was 
used as a standard. 
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 Enzyme activity 
The lactate dehydrogenase activity (LDH, EC 1.1.1.27) and alkaline phosphatase 
activity (ALP, EC 3.1.3.1) were measured using commercial kits (DG 1340-UV and 
DG 1245-UV, respectively, Sigma Diagnostics, Bornem, Belgium), and expressed as 
IU/l per gram body weight. The reagents measure the enzyme activity using an 
optimized method based on the standard method recommended by the German 
Society for Clinical Chemistry (DGKC, 1972). The activity measurements were 
conducted on a Cobas Plus analyser (ABX, Brussels, Belgium) at 37 °C. 
 
Stinging, itching and burning (SIB) test procedure of the SMI-test  
This new test procedure is a modified version of the previously described method, 
only focusing on the occurrence of SIB-sensations. In this 1-day experiment, there 
are 3 CPs of 15 min, with 1 h rest/ recovery period in between. For each series, 3 
slugs are used. During each CP, the slugs are placed on a Petri dish on 100 µl of the 
undiluted test substance. Body weight and MP are determined as described for the 
local tolerance experiment. No samples are taken to analyze protein or enzyme 
release. In the experiments PBS was used as a negative control, whereas a 1% (w/v) 
dilution of BAC was used as a positive control, as were in the 5-day protocol. 
 
Osmolality measurements 
The osmolality of the test compounds was measured using an Advanced Micro 
Osmometer (Model 3300 Advanced Instruments Inc, Norwood, MA, US) by the 
freezing-point method. Clinitrol™ 290 was used as reference solution (Advanced 
Instruments). The measurements were performed in triplicate (on 20-µL aliquots) and 
mean values used for analysis. Results are represented as mOsm/kg. Samples with 
an osmolality > 1200 mOsm/kg were diluted for measurement. 
 
Data analysis 
8 
 
For the 5-day procedure the irritation potency was predicted based on the total 
amount of mucus produced (total MP) during the repeated 30 min CPs. Total MP is 
expressed as a percent of the body weight of the slugs. For each slug, total MP is 
calculated by adding up the mucus produced during each 30 min CP, and a mean 
value for the slugs in each treatment was calculated. The cut-off values for 
classification are shown in Table 2. Tissue damage is predicted by: the number of 
slugs in each treatment group (out of the 5 per treatment) that show ALP release; the 
mean LDH release of all the samples; and the mean protein release excluding the 
samples taken on day 1 (Fig. 1). 
Classification in the newly developed test method for SIB is based on the MP only. 
The cut-off values are based on the mean total MP of the 3 CPs (Table 2). 
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Results 
Local tolerance of nasal formulations 
The 5-day test procedure was used to evaluate the mucosal tolerance of liquid nasal 
formulations. The effects of a daily 30 min exposure to the test substances on the 
total MP, mean protein and enzyme release are presented in Table 3. 
None of the tested liquid nasal formulations caused tissue damage (mean protein 
release < 25 µg/ml.g; no LDH or ALP release) as did the negative control PBS. On 
the other hand, severe tissue damage was observed in the positive control BAC 1% 
(mean protein release > 100 µg/ml.g; LDH > 4 IU/g; ALP observed in 1 slug). From 
day 1 on, LDH release was already observed. Release of this marker increased in 
function of time. On the other hand, ALP release was detected on day 4 in only 1 of 
the 5 slugs treated with this solution. The next day this slug was found dead, 
indicating some severe tissue damage had occurred. 
The exposure to the different formulations had a clear effect on the MP of the slugs. 
Mometazone furoate (Nasonex®) and fluticasone propionate (Flixonase Aqua™) 
showed a comparable total MP and were classified as mild irritants. Oxymetazoline 
HCl 0.01% (Nesivine® Baby) and oxymetazoline HCl 0.05% (Nesivine®) were both 
classified as moderate irritants (total MP between 5 and 10%). A slight concentration-
response effect was observed, with MP in oxymetazoline HCl 0.05% (Nesivine®) 
slightly higher than for oxymetazoline HCl 0.01% (Nesivine® Baby). Both azelastine 
HCl (Allergodil®) and flunisolide (Syntaris®) caused severe irritation in the slugs 
(total MP > 10%).  
The effects on the MP are in most cases due to the active ingredient, while for 
Syntaris® the high tonicity (1592 ± 28 mOsm/kg) is the probable cause. It is quite 
striking that the elevated MP for Syntaris® was not accompanied with protein and 
enzyme release, indicating stinging, itching, and/or burning might have occurred 
without any tissue damage.  
   
Possible influence of BAC-concentration and osmolality 
The influence of osmolality and the BAC-concentration was also investigated with the 
5-day test procedure. Results are presented in Table 4.  
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A concentration-response experiment was conducted testing the irritation potency of 
BAC in concentrations of 0.02%, 0.1%, 0.5% and 1%. There was a clear effect of 
BAC-concentration on the reaction of the slugs. Irritation was observed in all tested 
concentrations. Even BAC 0.02% resulted in moderate irritation (total MP between 
5% and 10%), while the other 3 concentrations were classified as severe irritant (total 
MP > 10%). There was no tissue damage in BAC 0.02% and BAC 0.1% (mean 
protein release < 25 µg/ml.g; no LDH and ALP release). On the other hand, BAC 
0.5% and BAC 1% resulted both in severe tissue damage (mean protein release > 
100 µg/ml.g; ALP and LDH release). 
Another concentration-response experiment with 6 different NaCl-concentrations was 
conducted as well. This was done to deduce the effect of tonicity on the reaction of 
the slugs. First, none of the NaCl-solutions resulted in tissue damage (mean protein 
release < 25 µg/ml.g; no LDH or ALP release). A second observation is the fact that 
the 3 lowest concentrations (0.05%, 0.5% and 0.9%) did not cause any irritation 
either (total MP < 0%). For all 3 concentrations, total MP was even negative, 
probably due to the osmotic effect, since hypotonicity results in some fluid take-up by 
the slugs, giving a very low or even negative MP, as is the case here. The 2.5%-NaCl 
solution resulted in moderate irritation, while both 5%- and 10%-NaCl solutions 
caused severe irritation (total MP > 10%). 
 
Stinging, itching and burning of liquid nasal formulations 
In this first part, the same liquid nasal formulations as tested with the local tolerance 
test procedure were investigated. Results are presented in Table 5. All formulations 
showed a higher MP than the negative control (PBS). With this protocol mometasone 
furoate (Nasonex®), fluticasone propionate (Flixonase Aqua™), oxymetazoline 
0.01% (Nesivine® Baby), and oxymetazoline 0.05% (Nesivine®) were all classified 
as causing mild discomfort (total MP between 3% and 8%). Azelastine HCl 
(Allergodil®) and flunisolide (Syntaris®) showed a more elevated MP (total MP 
between 8% and 15%) and were therefore classified as causing moderate 
discomfort. It is clear that in most of the formulations the elevated MP is caused as a 
response to the active ingredient, while in the case of flunisolide (Syntaris®) the 
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reaction is associated with the high osmolality of the formulation. All the other 
formulations are practically isotonic. 
Stinging, itching and burning of physiological saline solutions 
In a second part, nasal physiological saline solutions were also tested with the newly 
developed protocol. Results are also presented in Table 5.  All practically isotonic 
solutions had a MP comparable with the negative control (total MP < 3%). Therefore, 
Naaprep®, Rhina-Care and Physiomer® Normal Jet were classified as causing no 
discomfort. Hypertonic saline solutions (630 mOsm/kg < osmolality < 750 mOsm/kg) 
(Physiomer® Sinus and Sinomarin®) resulted in an elevated MP (total MP between 
3% and 8%), and consequently being classified as causing mild discomfort (total MP 
between 3% and 8%).  
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Discussion 
In this study, the mucosal tolerance of several nasal formulations was evaluated with 
a 5-day repeated exposure study using the SMI assay. In the second part, the newly 
developed 1-day protocol of the SMI assay for the detection of short term sensations 
(stinging, itching and burning) was evaluated by testing several marketed 
physiological saline solutions with a different tonicity, as well as the nasal 
formulations tested with the 5-day protocol. Additionally, the effect of tonicity and the 
concentration of BAC on the slugs were investigated into detail with both testing 
procedures.  
In many multidose topical aqueous nose drop and spray formulations, BAC is used 
as a preservative to prevent bacterial contamination and maintain the safety of the 
preparations (Graf, 2005; Graf et al., 1995, 1999; Marple et al., 2004; Steinsvåg et 
al., 1996). Benzalkonium chloride acts by damaging the cell wall of micro-organisms, 
by altering its permeability (Richards & Cavill, 1976). In multidose marketed nasal 
products, BAC is usually added in concentrations of 0.005 - 0.02% (w/v) 
(Riechelmann et al., 2004; Verse et al., 2003), while the American College of 
Toxicology concluded that BAC can be used safely in a concentration up to 0.1% 
(w/v). However, some reports suggest that the presence of BAC in a formulation may 
induce severe morphological and histological changes, both in vitro and in vivo (e.g. 
Berg et al., 1995; Cüreoğlu et al., 2002; Kuboyama et al., 1997; Lebe et al., 2004; 
Riechelmann et al., 2004). In addition, according to some authors, decongestant 
nasal sprays with BAC aggravate rhinitis medicamentosa by causing increased 
swelling of nasal epithelium (Graf, 1999; Graf et al., 1995; Hallén & Graf, 1995). 
Results from the SMI-tests reveal a concentration response effect, which has also 
been observed by Berg et al. (1995), Lebe et al. (2004) and Marple et al. (2004). In 
slugs, high concentrations of BAC result in a very high MP and cause significant 
tissue damage, while for lower concentrations only an elevated MP is seen, without 
tissue damage being observed. This increased MP in lower concentrations is 
presumably induced by a stinging or burning sensation. Riechelmann et al. (2004) 
evaluated the adverse effects of BAC on human nasal mucosa, both in vitro and in 
vivo. In vitro, BAC in a concentration of 0.01% and 0.025% appeared to be ciliotoxic 
for human nasal respiratory epithelia from healthy, non-allergic volunteers. In vivo 
however, BAC did not interfere with nasal mucus transport and did not induce nasal 
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inflammatory alterations compared to the placebo. However, directly after application, 
0.05% BAC caused nasal irritation, hypersecretion and a burning sensation. 
Moreover, scores for persistent nasal irritation were higher for BAC than the placebo.  
In this current study, all tested liquid nasal formulations only demonstrated an effect 
on the MP, without inducing tissue damage. This increase in MP may be caused by 
the irritability and toxicity of a certain ingredient on the one hand, as described above 
for BAC, while on the other hand tonicity of the preparations may play an important 
role as well. A mild irritating effect in slugs was observed for mometasone furoate 
(Nasonex®) and fluticasone propionate (Flixonase Aqua®) nasal sprays. Probably 
these reactions were mainly caused by the presence of BAC in the formulation, since 
an isotonic 0.02% BAC solution alone induced a comparable reaction in slugs, as 
was seen for the mometasone furoate and fluticasone propionate nasal sprays. 
Generally, mometasone furoate and fluticasone propionate nasal sprays are clinically 
well tolerated (e.g. Bronsky et al., 1997; Grossman et al., 1993; Hebert et al., 1996; 
Holm et al., 1998; Kerwin et al., 2008; Mandl et al., 1997) with a very low frequency 
of reported local adverse events, which in most cases was comparable to the control 
group (Table 6). 
Exposure of the slugs to an oxymetazoline HCl spray induced a higher MP than 
mometasone furoate and fluticasone propionate sprays. Two concentrations of 
oxymetazoline HCl were tested (0.01% (Nesivine® Baby) and 0.05% (Nesivine®)), 
with the highest concentration containing BAC as a preservative in an unknown 
concentration. The slugs’ reaction was concentration dependent, and might even be 
enhanced by the presence of BAC, resulting in a greater MP observed for 0.05% 
oxymetazoline HCl. These results show that oxymetazoline as such also induces a 
mildly irritating effect. In literature, the (over)use of oxymetazoline HCl is often 
described to be related with RM (e.g. Graf & Juto, 1994a, 1994b, 1995). Opinions 
vary as to how long topical decongestants can safely be used without risking the 
development of RM (Graf et al., 1999), as the recommended usage of topical 
decongestants varies globally (Morris et al., 1997). In the current study, a slight time 
dependent effect of oxymetazoline HCl was observed in the 5-day test. After the fifth 
CP protein release exceeded 25 µg/ml.g, a phenomenon which has never been 
observed in slugs treated with PBS or other non-irritating substances. In this context, 
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a 2- or 3-week lasting SMI-experiment might provide insight in the effect of 
oxymetazoline HCl on the longer term. 
The tested azelastine HCl nasal spray (Allergodil®) induced an elevated MP in slugs, 
probably caused by the active ingredient itself, since the spray did not contain BAC 
as a preservative. Generally, azelastine HCl is well tolerated, however some 
commonly reported adverse events associated with the use of intranasal azelastine 
include irritation of the nasal mucosa and application site (e.g. Grossman et al., 1994; 
Lassig et al., 1996; Mösges et al., 1995; Wober et al., 1997), and nasal burning (e.g. 
Lumry et al., 2007; Newson-Smith et al., 1997) (Table 6). Nevertheless, all clinical 
trials cited above were done with patients suffering from (seasonal) AR, whose nasal 
mucosa is already affected, which may also influence the reaction of the patients. 
As mentioned before, an increased MP might also be explained as an effect of 
tonicity. Adriaens & Remon (2008) indicated that an increased osmolality resulted in 
more irritation in slugs. This is clearly the case for the flunisolide nasal spray 
(Syntaris® - 1592 ± 28 mOsm/kg). It induced a total MP of 19.7 ± 1.3% in the 5-day 
protocol and 12.4 ± 1.1% in the 1-day test. There is a strong similarity between these 
results and those of the tested 5%-NaCl solution (1544 ± 11 mOsm/kg), for which the 
MP totaled 19.1 ± 3.0% and 12.6 ± 0.7%, for the 5- and 1-day test respectively. 
These results indicate that we may conclude that the irritation of the flunisolide nasal 
spray is due to its hypertonicity. Supporting evidence of the effect of hypertonicity is 
given by the studies of, Adam et al. (1998), Baraniuk et al. (1999), Hauptman & Ryan 
(2007), Rabago et al. (2002) and Shoseyov et al. (1998) (Table 7). Thus, although 
generally safe, daily hypertonic nasal irrigation may be associated with some 
clinically minor side effects.  
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Conclusion 
We can conclude that the SMI-assay is a good tool to predict nasal clinical 
discomfort. The 5-day testing procedure is able to investigate the effect of a repeated 
exposure, focusing on both irritation and tissue damage, while the newly developed 
1-day procedure is capable to predict the likely occurrence of stinging, itching and/or 
burning sensations in man, quantified by total mucus production of the slugs. None of 
the tested marketed nasal formulations appeared to result in tissue damage, 
although moderate discomfort was observed in some cases. Generally there is a 
good agreement between the data obtained with the SMI-tests and published clinical 
data. Both SMI-test procedures gave the same ranking of the tested formulations; 
however the ranges were smaller, due to a difference in contact period, and 
consequently the total amount of mucus produced. Active ingredients, preservatives 
and osmolality appeared to play an important role in the reaction of the slugs.  
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Tables 
Table 1 Overview of the tested nasal formulations and their ingredients 
Product 
name 
Active ingredient Other ingredients 
Nasonex®*a 
Mometasone furoate (MOMF) 
0.05% 
colloidal cellulose, glycerol, 
sodium citrate dehydrate, citric 
acid monohydrate, polysorbate 
80, BAC, purified water 
Flixonase 
Aqua™*a 
Fluticasone propionate (FP) 
0.5% 
glucose, microcrystalline 
cellulose, sodium carboxymethyl-
cellulose, polysorbate 80, 
hydrochloric acid, phenylethyl 
alcohol, BAC, purified water 
Nesivine 
Baby®b 
Oxymetazoline hydrochloride 
(OXY) 0.01% 
monobasic sodium phosphate, 
dibasic sodium phosphate, 
sodium hydroxide, purified water 
Nesivine®*b 
Oxymetazoline hydrochloride 
(OXY) 0.05% 
sodium edate, BAC, monobasic 
sodium phosphate, dibasic 
sodium phosphate, sodium 
hydroxide, purified water 
Allergodil®b 
Azelastine hydrochloride (AZE) 
0.1% 
methyl hydroxyl propylcellulose, 
sodium edate, citric acid, dibasic 
sodium phosphate, sodium 
chloride and purified water 
Syntaris®*b Flunisolide (FS) 0.025% 
citric acid, BAC, butyl 
hydroxytoluene, polyethylene 
glycol 400, sodium citrate, sodium 
edate, polysorbate 20, propylene 
glycol, sorbitol, purified water 
*containing benzalkonium chloride (BAC); a suspension; b solution 
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Table 2 Classification criteria for irritation of the total mucus production (expressed as 
a % of initial body weight) for the 1-day stinging, itching and burning (SIB) protocol 
and 5-day local tolerance (LT) protocol 
1-day SIB 5-day LT Irritation 
< 3% < 0% Not 
3 – 8% 0 – 5% Mild 
8 – 15% 5 – 10% Moderate 
> 15% > 10% Severe 
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Table 3 Effect of a repeated treatment for 5 successive days with 100 µl of different 
liquid nasal formulations and control solutions on the endpoints of the Slug Mucosal 
Irritation (SMI) test 
Formulation 
Total 
mucus 
production 
(%) 
 
Irritation 
 
Mean 
protein 
release 
(µg/ml.g) 
 
Mean 
LDH 
release 
(IU/l.g) 
Number 
of 
slugs 
with 
ALP 
release 
Tissue 
damage 
 
Osmolality 
(mOsm/kg) 
   
 
PBSa -2.7 ± 1.2 
 
No 
 
9 ± 3 
  
- 
 
0 No  280 ± 1 
MOMF 0.05%*b 4.3 ± 1.8 
 
Mild 
 
24 ± 10 
  
- 
 
0 No  307 ± 4 
FP 0.05%*b 4.4 ± 1.1 
 
Mild 
 
12 ± 8 
  
- 
 
0 No  338 ± 1 
OXY 0,01%*a 6.8 ± 3.4 
 
Moderate 
 
13 ± 5 
  
- 
 
0 No  296 ± 2 
OXY 0,05%*a 8.4 ± 1.8 
 
Moderate 
 
12 ± 2 
  
- 
 
0 No  296 ± 2 
AZE 0.1%a 10.8 ± 1.6 
 
Severe 
 
21 ± 15 
  
- 
 
0 No  279 ± 2 
FS 0.025%*a 19.7 ± 1.3 
 
Severe 
 
16 ± 10 
  
- 
 
0 No  1592 ± 28 
1% BACa 28.8 ± 9.8 
 
Severe 
 
113 ± 24 
 
7.9 ± 2.5 1 Severe  291 ± 2 
Total mucus production, mean protein release and mean LDH release data are presented as the mean 
± standard deviation of 5 slugs; - , below the detection limit; PBS: phosphate buffered saline; BAC: 
benzalkonium chloride; MOMF: mometasone furoate; FP: fluticasone propionate; OXY: oxymetazoline 
HCl; AZE: azelastine HCl; FS: flunisolide; *: contains BAC; a: solution; b: suspension 
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Table 4 Effect of a repeated treatment for 5 successive days with 100 µl of BAC- and 
NaCl-solutions on the endpoints of the Slug Mucosal Irritation (SMI) test 
Formulation 
Total mucus 
production 
(%) 
 
Irritation 
 Mean 
protein 
release 
(µg/ml.g) 
 Mean 
LDH 
release 
(IU/l.g) 
Number 
of  slugs 
with 
ALP 
release 
Tissue 
damage 
 
Osmolality 
(mOsm/kg) 
   
 
BAC 0,02% 5.1 ± 2.7 
 
Moderate 
 
14 ± 4 
  
- 
 
0 No  279 ± 0 
BAC 0,1% 15.2 ± 2.7 
 
Severe 
 
19 ± 17 
  
- 
 
0 No  278 ± 2 
BAC 0,5% 32.2 ± 4.2 
 
Severe 
 
114 ± 53 
 
3 ± 2 2 Severe  284 ± 3 
BAC 1% 25.1 ± 1.7 
 
Severe 
 
151 ± 41 
 
8 ± 4 2 Severe  291 ± 2 
NaCl 0.05% -10.5 ± 1.7 
 
No 
 
11 ± 5 
  
- 
 
0 No  15 ± 1 
NaCl 0.5% -5.3 ± 1.2  No  14 ± 4   -  0 No  162 ± 1 
NaCl 0.9% -1.8 ± 2.1  No  19 ± 12   -  0 No  288 ± 6 
NaCl 2.5% 6.5 ± 1.2  Moderate  18 ± 6   -  0 No  763 ± 7 
NaCl 5% 19.1 ± 3.0  Severe  23 ± 11   -  0 No  1544 ± 11 
NaCl 10% 37.3 ± 8.5  Severe  24 ± 12   -  0 No  2912 ± 45 
Total mucus production, mean protein release and mean LDH release data are presented as the mean 
± standard deviation of 5 slugs; -: below detection limit; BAC: benzalkonium chloride 
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Table 5 Effect of a repeated treatment (3 contact periods of 15 min on the same day) 
of 6 liquid nasal formulations, 5 physiological saline solutions and several 
concentrations of BAC and NaCl on the endpoints of the Slug Mucosal Irritation (SMI) 
test to detect SIB sensations 
Product 
Total mucus 
production 
(%)  
Discomfort  
Osmolality 
(mOsm/kg) 
PBSa 0.0 ± 1.0 
 
No  280 ± 1 
BAC 1%*a 25.3 ± 3.4 
 
Severe  291 ± 2 
MOMF 0.05%*b 3.6 ± 1.3 
 
Mild  307 ± 4 
FP 0.05%*b 4.8 ± 0.1 
 
Mild  338 ± 1 
OXY 0,01%*a 5.6 ± 0.5 
 
Mild  296 ± 2 
OXY 0,05%*a 6.0 ± 0.1 
 
Mild  296 ± 2 
AZE  0.1%a 7.6 ± 0.9 
 
Mild  279 ± 2 
FS 0.025%*a 12.4 ± 1.1 
 
Moderate  1592 ± 28 
Naaprep® (0.9% NaCla) 0.4 ± 0.7 
 
No  287 ± 2 
Rhina-Care (0.9% NaCla) 0.4 ± 0.5  No  297 ± 3 
Physiomer® Normal Jet (0.9% NaCla) 0.8 ± 1.2  No  326 ± 2 
Physiomer® Sinus (2.2% NaCla) 3.9 ± 0.2  Mild  638 ± 5 
Sinomarin® (2.3% NaCla) 4.0 ± 1.0  Mild  726 ± 3 
BAC 0,02%*a 4.1 ± 0.8  Mild  279 ± 0 
BAC 0,1%*a 10.8 ± 0.9  Moderate  278 ± 2 
BAC 0,5%*a 22.9 ± 3.4  Severe  284 ± 3 
NaCl 0.05%a -3.7 ± 0.5  No  15 ± 1 
NaCl 0.5%a -1.9 ± 0.3  No  162 ± 1 
NaCl 0.9%a -0.2 ± 0.5  No  288 ± 6 
NaCl 2.5%a 3.5 ± 0.5  Mild  763 ± 7 
NaCl 5%a 12.6 ± 0.7  Moderate  1544 ± 11 
NaCl 10%a 19.2 ± 2.4  Severe  2912 ± 45 
Total mucus production presented as the mean ± standard deviation of 3 slugs; BAC: 
benzalkonium chloride; MOMF: mometasone furoate; FLP: fluticasone propionate; 
OXY: oxymetazoline; AZE: azelastine HCl; FLS: flunisolide; *: contains BAC; a: 
solution; b: suspension 
 
 
 
 
 
26 
 
Table 6 Comparison if irritation categories obtained with the Slug Mucosal Irritation assay (SIB protocol) with clinical data 
concerning nasal irritation or burning sensation induced by a repeated treatment (1 week up to 1 year) with some liquid nasal 
formulations 
Active ingredient 
Discomfort 
category 
SMI 
Dose  
Clinical data 
Patients with nasal 
irritation or burning (%) 
Patients (n) Source 
Mometasone furoate (MOMF)  
0.05% = mild 
 
 
placebo, 50 µg, 100 µg, 200 µg, 800 µg 2, 5, 4, 3, 4 95, 96, 95, 98, 95 Bronsky et al. (1997) 
placebo, 100 µg, 200 µg 5, 6, 3 123, 126, 126 Hebert et al. (1996) 
placebo, 200 µg 7, 3 184, 181 Mandl et al. (1997) 
Fluticasone propionate (FP)  
0.05% = mild 
 
placebo, 100 µg, 200 µg 0, 4, 1 85, 84, 81 Grossman et al. (1993) 
placebo, 100 µg bid 57*, 62* 12, 17 Holm et al. (1998) 
placebo, 250 µg 1, 0 212, 212 Kerwin et al. (2008) 
placebo, 200 µg 7, 3  184, 183 Mandl et al. (1997) 
Azelastine HCl (AZE)  0.1% = mild 
 
140 µg per nostril bid 8 489 Lassig et al. (1996) 
280 µg per nostril bid (14 days, 31 days) 1.4, 1.2 3680, 4002 Wober et al. (1997) 
placebo, 2 mg bid 84*, 136* 65, 68 Grossman et al. (1994) 
placebo, 137 µg per nostril bid 0, 0.4 278, 276 Lumry et al. (2007) 
placebo, 280 µg per nostril bid 0, 1 77, 83 Newson-Smith et al. (1997) 
1 mg/ml per nostril bid 5.1 119 Mösges et al. (1995) 
*: represent total % of all reported adverse experiences 
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Table 7 Comparison of irritation categories obtained with the Slug Mucosal Irritation assay (SIB protocol) with clinical data concerning nasal 
irritation or burning sensations or general adverse events induced by a (repeated) treatment (1 day up to 6 months) with liquid nasal saline 
solutions 
Concentration 
NaCl (%) Discomfort category SMI 
Clinical data 
Patients with nasal irritation or burning (%) 
or general adverse events or observations 
if not specified otherwise 
Patients 
(n) 
Source 
0.9 & 3.5 0.9% = no, 5% = moderate 0.9% < 3.5%  15, 15 Shoseyov et al. (1998) 
0.9 & 2 0.9% = no, 2.5% = mild 13, 32 31, 33 Adam et al. (1998) 
2 2.5% = mild 18 44 Rabago et al.(2002) 
0.9 & 3 0.9% = no, 2.5% = mild 0.9% < 3% 40, 40 Hauptman & Ryan (2007) 
0.9, 2.7, 5.4, 10.8 0.9% = no, 2.5% = mild, 5% = moderate, 10% = severe 0.9% < 2.7% < 5.4% < 10.8% 29 Baraniuk et al. (1999) 
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Figures  
 
Figure 1 Classification prediction model for 5-day Local Tolerance testing procedure 
for tissue damage 
 
